News for Theralase Technologies Inc. (TLT.V)

Theralase Technologies (TSXV: TLT) (OTCQB: TLTFF) successfully raises CAN $419,124 in a non-brokered private placement. Proceeds to support Phase II Non-Mus

Theralase Technologies Inc. (OTCQX:TLTFF) Q4 2024 Earnings Conference Call March 19, 2025 11:00 AM ETCompany ParticipantsMatthew Perraton - Chairman of the...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Viru

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infectio

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of The

St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NTLT.V - Theralase Technologies IncQ3 2024 Theralase Technologies Inc Earnings CallDec 04, 2024

Theralase Technologies Inc. (OTCQX:TLTFF) Q3 2024 Earnings Conference Call December 4, 2024 11:00 AM ETCompany ParticipantsMatthew Perraton - Chairman of...

TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage phar

Total Revenue: Decreased 30.5% year over year.Cost of Sales: $186,324 or 67% of revenue.Gross Margin: $90,077 or 33% of revenue.Selling Expenses: Decreased to

Aug 21, 2024 / 03:00PM GMTMatthew Perraton - Theralase Technologies Inc - Independent Chairman of the Board Good morning, everyone. My name is Matthew Perraton,

Theralase Technologies Inc. (OTCQX:TLTFF) Q2 2024 Earnings Conference Call August 21, 2024 11:00 AM ETCompany ParticipantsMatthew Perraton - Chairman of the...

“Photodynamic Therapy Devices Market” from 2024-2034 with covered segments By Product Type (Photosensitizer Drugs, Aminolevulinic Acid, Porphyrin...

One of the primary growth drivers for the PDT market is the rising incidence of cancer and skin diseases globally. PDT is particularly effective in...

/PRNewswire/ -- The photodynamic therapy market size to grow by USD 2,053.68 million from 2022 to 2027, progressing at a CAGR of 8.22% during the forecast...

Emerging applications in ophthalmology is a major factor that is anticipated to escalate the photodynamic therapy market growth...

An increase in the prevalence of various skin diseases, such as psoriasis, actinic keratosis, acne, rosacea, and others is leading to the growth of the...

VANCOUVER, BC, Jan. 8, 2021 /CNW/ -TSX VENTURE COMPANIESHAW CAPITAL 2 CORP. ('HAW.P')BULLETIN TYPE:  Resume TradingBULLETIN DATE:  January 8, 2021...